EC Number   |
Protein Variants |
Reference |
|---|
    1.2.1.12 | A229V |
exhibits 50-55% residual activity in blood compared to the wild type enzyme |
688791 |
| 1.2.1.12 | C149A |
mutant enzyme displays no significant dehydrogenase activity |
656119 |
| 1.2.1.12 | C149A |
mutant has almost completely lost the ability to bind telomere. Upon expression in A-549 cells, mutant localizes to the nucleus but is unable to confer any significant protection of telomeres against chemotherapy-induced degradation or growth inhibition |
699592 |
| 1.2.1.12 | C149A |
mutation abolishes NAD+-dependent ADP-ribosylation of the enzyme |
698374 |
| 1.2.1.12 | C149A |
site-directed mutagenesis |
742668 |
| 1.2.1.12 | C149S |
about 1% of wild-type activity, residue Cys149 is both essential for catalysis and the only accessible cysteine |
724236 |
| 1.2.1.12 | C149S |
low but significant phosphorylating dehydrogenase activity |
656119 |
| 1.2.1.12 | C149S |
the mutant shows 92% activity compared to the wild type enzyme |
724236 |
| 1.2.1.12 | C149S |
treatment of with (E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide at 0.1 mM leads to low levels of aggregation (5% of wild type) |
687602 |
| 1.2.1.12 | C149S/C281S |
mutant shows a complete absence of aggregation in the presence of (E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide |
687602 |
